Professor Mondher Toumi, MD, MSc, PhD – Mondher initially trained as a Medical Doctor and subsequently obtained an MSc in Biological Sciences (option pharmacology), an MSc iniostatistics and a PhD in Economic Sciences. He isProfessor of Public Health at Aix-Marseille University. He started his career at the University of Marseille, first in the Department of Pharmacology, and later in the Public Health Department. In 1995, he entered the pharmaceutical industry. Mondher was appointed Global Vice President at Lundbeck A/S in charge of health economics, outcomes research, pricing, market access, epidemiology, risk management, governmental affairs, and competitive intelligence. In 2008, he founded Creativ-Ceutical, an international consulting firm dedicated to support life sciences companies and authorities in strategic decision-making. He launched the European University Diploma of Market Access (EMAUD), the first international course on market access, already followed by more than 350 students. He is Editor in Chief of the Journal of Market Access and Health Policy (JMAHP). Mondher Toumi also held the position of VisitingProfessor at Beijing University (Third Hospital). He is a recognized expert in health economics and anauthority on market access and risk management. He has authored more than 200 scientific articles, and several books, including an “Introduction to Market Access for Pharmaceutical” (CRC Press, 2017).

Samuel holds a post-graduate degree in Biostatistics (ENSAI, France), an MSc in Health Economics (University of York, UK) and a PhD in Economic Sciences (University of Lyon 1, France). Samuel worked for 20 years as a consultant in Health Economics and Outcomes Research (HEOR). Before founding InnovIntel with Professor Toumi, he was Senior Vice-President and Chief Scientific Officer as Creativ-Ceutical. He managed or directed many health economic and epidemiological research projects, including the development of core models, multi-country patient preference studies, network meta-analyses of clinical trials and real-world evidence (RWE) studies. His expertise focuses on the application of quantitative methods in the context of the value assessment of health care interventions. He has authored near 100 journal publications in the field of HEOR. Samuel is currently based in the Netherlands and previously worked in the UK and France.

Alexander Bakhutashvili is M.D., M.Sc. and Ph.D. in Allergy and Immunology. After graduation from the Moscow Medical University he devoted next 8 years to basic research in The Institute of Medical Biotechnology of Georgian Academy of Science. In 1991 he became a founder of the first private pharmaceutical manufacturing company in Georgia. In 1995 he relocated to Russian Federation and founded several pharmaceutical companies including Arbacom, Ltd. – one of the leading distributors and manufacturers of pharmaceutical products, and Valexpharm Ltd – an R&D company geared towards development and introduction to the market of original drugs. In 2006 these companies were sold to financial institutions. Later on (2005-2009) he was invited to run a consolidated pharmaceutical business for one of the largest Russian financial conglomerate, listed on London Stock Exchange Russian public company FSC “Systema”. He was member of the executive board of FSC “Systema” and CEO of ZAO “Binnopharm”. Being CEO of ZAO “Binnopharm” he was involved with personnel management, construction and setting up of pharmaceutical facilities, pharmaceutical manufacturing and sales of pharmaceutical products. At the present time Alexander Bakhutashvili has concentrate his efforts on development of innovative drugs and drug repositioning as a President of Valexpharm Ltd., Member of Board and Chief Scientific Officer of Marco Polo Pharmaceuticals, a Luxembourg based drug- repositioning company. His business expertise field is pharmaceutical market economy, market access and drug development.